Granulocytapheresis in the treatment of patients with active ulcerative colitis

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 5, 2008, Pages 639-643

  Bresci, Giampaolo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Granulocytapheresis; Leukocytapheresis; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTAPHERESIS; DISEASE ACTIVITY; DRUG MEGADOSE; GRANULOCYTAPHERESIS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; INTESTINE MUCOSA; LEUKOCYTE MIGRATION; MAINTENANCE THERAPY; PATIENT SAFETY; PLACEBO EFFECT; REMISSION; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; CELL MOVEMENT; COLITIS, ULCERATIVE; CYTAPHERESIS; GRANULOCYTES; HUMANS; INTESTINAL MUCOSA;

EID: 55449136366     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.5.639     Document Type: Review

References (60)

1. Saverymuttu SH, Chadwick VS, Hodgson HJ. Granulocyte migration in ulcerative colitis. Eur. J. Clin. Invest. 15(2), 60-63 (1985).
2. Saverymuttu SH, Peters AM, Crofton ME et al. 111Indium autologous granulocytes in the direction of inflammatory bowel disease. Gut 26(9), 955-960 (1985).
3. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 35(5), 669-674 (1994).
4. Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S. Increased expression of IL-16 in inflammatory bowel disease. Gut 48 (3), 326-332 (2001).
5. Nielsen OH, Rudiger N, Gaustadnes M, Horn T. Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease. Scand. J. Gastroenterol. 32(10), 1028-1034 (1997).
6. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neuttophils and regulation by interleukin-10 during intestinal inflammation. Gut 42 (4), 470-476 (1998).
7. Janczewska I, Stal P, Sandstedt B. Transformation of microscopic colitis to inflammatory bowel disease. Lakartidningen. 104(20,21), 1597-1598 (2007).
8. Nusrat A, Tumer JR, Madara JL. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am. J. Physiol. Gastrointest. Liver Physiol. 279(5), G851-G857 (2000).
9. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 124(4), 1164-1165 (2003)
10. Hanai H, Takeuchi K, Iida T et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci. 49(9), 1438-1443 (2004).
11. Berni CR, Terrin G, Rapacciuolo L et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dis Liver Dis. 40 (7), 547-553 (2008).
12. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on therapeutic trial. Br. Med. J. 2, 1041-1048 (1955).
13. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators and infliximab in inflammatory bowel disease. Gastroenterology 130, 935-939 (2006).
14. Porto GB, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment. Pharmacol. Ther. 26(6), 779-794 (2007).
15. Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med. J. Aust. 49, 592-593 (1962).
16. Bowen GE, Irons GV, Rhodes JB. Early experiences with azathioprine in ulcerative colitis. A note of caution. JAMA 195, 460-464 (1966).
17. Lichtiger S, Present DH, Kornbluth A. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330, 1841-1845 (1994).
18. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol. Clin. North Am. 33(2), 209-234, viii (2004).
19. Gourlay T, Olivencia-Yurvati AH, Gunaydin S. STS blood conservation guidelines: the role of leukocyte filtration. Ann. Thorac. Surg. 85(3), 1138-1139 (2008).
20. Bosch T. Therapeutic apheresis-state of the art in the year 2005. Ther. Apher. Dial. 9(6), 459-468 (2005).
21. Kennedy MS, Domen RE. Therapeutic apheresis. Applications and future directions. Vox Sang. 45, 261-277 (1983).
22. Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41(10), 874-888 (2007).
23. Sawada K, Muto T, Shimoyama T et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr. Pharm. Des. 9(4), 307-321 (2003).
24. Nishioka C, Aoyama N, Maekawa S et al. Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J. Gastroenterol. Hepatol. 20(10), 1567-1571 (2005).
25. Fukunaga K, Sawada K, Chikano S et al. [Leukocytapheresis for ulcerative colitis]. Nippon Rinsho. 57(11), 2496-2502 (1999).
26. Sawada K, Kusugami K, Suzuki Y et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. 100(6), 1362-1369 (2005).
27. Sawada K, Ohnishi K, Fukunaga K et al. [Mechanism of leukocytapheresis effect in the treatment of ulcerative colitis]. Nihon Rinsho Meneki Gakkai Kaishi 22 (6), 469-474 (1999).
28. Sawada K, Ohnishi K, Kosaka T et al. [Leukocytapheresis for ulcerative colitis]. Nippon Geka Gakkai Zasshi 98(4), 438-442 (1997).
29. Emmrich J, Petermann S, Nowak D et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis-results of a randomized pilot trial. Dig. Dis. Sci. 52(9), 2044-2053 (2007).
30. Ramlow W, Emmrich J, Ahrenholz P et al. In vitro and in vivo evaluation of Adacolumn cytapheresis in healthy subjects. J. Clin. Apher. 20(2), 72-80 (2005).
31. Saniabadi AR, Hanai H, Takeuchi K et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther. Apher. Dial. 7(1), 48-59 (2003).
32. Saniabadi AR, Hanai H, Fukunaga K et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus. Apher. Sci. 37(2), 191-200 (2007).
33. Yamamoto T, Umegae S, Kitagawa T et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment. Pharmacol. Ther. 20(7), 783-792 (2004).
34. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig. Liver Dis. 36(12), 811-817 (2004).
35. Domènech E, Hinojosa J, Esteve-Comas M et al.; Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment. Pharmacol. Ther. 20(11,12), 1347-1352 (2004).
36. Sands BE, Sandborn WJ, Wolf DC et al. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J. Clin. Gastroenterol. 40(6), 482-489 (2006).
37. Kashiwagi N, Sugimura K, Koiwai H et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig. Dis. Sci. 47(6), 1334-1341 (2002).
38. Saniabadi AR, Hanai H, Suzuki Y et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J. Clin. Apher. 20(3), 171-184 (2005).
39. Hiraishi K, Takeda Y, Shiobara N et al. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther. Apher. Dial. 7(3), 334-340 (2003).
40. Soerensen H, Schneidewind-Mueller JM, Lange D et al. Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus etythematosus. Rheumatol. Int. 26(5), 409-415 (2006).
41. Yamaji K, Tsuda H, Hashimoto H. Current topics on cytapheresis technologica. Ther. Apher. 5(4), 287-292 (2001).
42. Ohara M, Saniabadi AR, Kokuma S et al. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif. Organs 21(9), 989-994 (1997).
43. Yonekawa M, Kawamura A, Komai T, Agishi T, Adachi M. Extracorporeal granulocytapheresis for cancer and rheumatoid arthritis. Transfus. Sci. 17(3), 463-472 (1996).
44. Sawada K, Ohnishi K, Kosaka T et al. Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J. Gastroenterol. 30(Suppl. 8), 124-127 (1995).
45. Sawada K, Ohnishi K, Fukui S et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J. Gastroenterol. 30(3), 322-329 (1995).
46. Kawamura A, Saitoh M, Yonekawa M et al. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease. Ther. Apher. 3(4), 334-337 (1999).
47. Shimoyama T, Sawada K, Hiwatashi N et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J. Clin. Apher. 16(1), 1-9 (2001).
48. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig. Liver Dis. 36(12), 811-817 (2004).
49. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig. Dis. Sci. 49(4), 565-571 (2004).
50. Sawada K, Kazuo K, Suzuki Y et al. Leukocytapheresis in ulcerative colitis: results of multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. 100(6), 1362-1369 (2005).
51. Hanai H, Watanabe F, Takeuchi K et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin. Gastroenterol. Hepatol. 1(1), 28-35 (2003).
52. Hanai H, Watanabe F, Yamada M et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 70 (1), 36-44 (2004).
53. Naganuma M, Funakoshi S, Sakuraba A et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm. Bowel Dis. 10(3), 251-257 (2004).
54. Kruis W, Dignass A, Steinhagen-Thiessen E et al. Open label trial of granulocyte apheresis suggests therapeutic efficay in cronically active steroid refractory ulcerative colitis. World J. Gastroenterol. 11 (44), 7001-7006 (2005).
55. Bresci G, Parisi G, Bertoni M, Mazzoni A, Scatena F, Capria A. Treatment with granulocytapheresis of active steroid-refractory inflammatory bowel diseases. Our experience with a prospective study. World J. Gastroenterol. 12(14), 2201-2204: (2006).
56. D'Ovidio V, Aratari A, Viscido A et al. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis. Dig. Liver Dis. 38, 389-394 (2006).
57. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy versus granulocytapheresis. A pilot study. Dig. Liver Dis. 39, 430-434 (2007).
58. Ljung T, Thomsen OØ, Vatn M et al. Granulocyte, monocyte/ macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand. J. Gastroenterol. 42 (2), 221-227 (2007).
59. Panés J, Guilera M, Ginard D et al. Treatment cost of ulcerative colitis. Is apheresis with Adacolumn cost-effective? Dig. Liver Dis. 39, 617-625 (2007).
60. Cabriada JL, Doménech E, Gomollón F et al. Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease. Gastroenterol. Hepatol. 29(2), 85-92 (2006).